April 29, 2020
GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today the first reverse total shoulder arthroplasty (rTSA) cases using Equinoxe® with VERASENSE®, a wireless humeral sensor manufactured by OrthoSensor Inc. The data it provides enables surgeons to make more-informed decisions on joint tension and implant sizing in real time, with the goal of improving joint performance, shoulder kinetics and patient satisfaction.
VERASENSE is the first and only technology that can intra-operatively measure joint tension in the shoulder and is used for various rTSA implant size configurations. Based on clinical history of use in the knee, it utilizes proprietary sensor technologies to transmit data wirelessly to an intra-operative monitor.
Orthopaedic surgeons Allan Wang, MD, and Sven Goebel, MD, of Perth, Australia, performed the two surgeries. “We found that using the sensors improved assessment of joint pressure during surgery,” Dr. Wang said. “Objective and real-time feedback of joint compression loads throughout range of motion can assist the surgeon in choosing the correct implant offset and soft tissue tension.”
“We believe that use of the sensor may lead to improved clinical outcomes and patient satisfaction,” added Dr. Goebel.
“OrthoSensor and Exactech chose to exclusively collaborate to build on the success of the groundbreaking Equinoxe shoulder – a market-leading platform shoulder system with a decade of clinical history and more than 100 peer-reviewed publications,” said Chris Roche, Vice President of Exactech’s Extremities business unit. “Both companies are committed to improving patient outcomes by using our innovative technologies together to identify the optimal joint tension when reducing a reverse shoulder.”
The VERASENSE wireless humeral sensor allows unconstrained evaluation of glenohumeral joint stability and kinetics. It displays load tracking in conjunction with numerical load data to visualize glenohumeral articulation through the full range of motion. The technology enables intra-operative data capture and does not require a change in the surgical workflow.
This device is currently undergoing premarket review by the Food and Drug Administration.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases, such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.
Priscilla Bennett, APR
Vice President, Corporate & Marketing Communication